Medication therapy works best when it’s paired with ongoing lifestyle support in obesity care – especially when we’re talking about GLP‑1s. The Omada Insights Lab evaluated outcomes in the Enhanced GLP-1 Care Track at one year, and found that persistence rates and weight loss surpassed published real-world estimates.
Key findings include:
✓ 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials.
✓ Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year.
✓ Members completed more than 10 actions a week on average.
For additional details on these findings and Omada’s Enhanced GLP‑1 Care Track, please connect with your account manager or contact a member of our sales leadership team.
